These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Not reported||2004-001449-13||Safety and Efficacy of XM 02 in patients with Non-Hodgkin-Lymphoma receiving chemotherapy.||2006-05-31||due-trials|
|Not reported||2004-001450-84||Safety and Efficacy of XM 02 in patients with small cell or non small cell lung cancer receiving platinum-based chemotherapy. Multinational, multicentre, randomised, controlled study||2006-04-19||due-trials|
|Not reported||2004-001452-36||Efficacy and Safety of XM 02 compared to Filgrastim in patients with breast cancer receiving chemotherapy. Multinational, multicentre, randomised, controlled study||2006-04-19||due-trials|
|Not reported||2005-000140-85||Efficacy and Safety of subcutaneous administration of XM01 and Epoetin beta for treatment of anaemia in chronic renal failure patients not yet receiving dialysis. A multinational, multicentre, randomi...||2007-03-20||due-trials|
|Not reported||2005-000142-37||Efficacy and Safety of subcutaneous administration of XM01 compared to Epoetin beta in anaemic chronic renal failure patients not yet receiving dialysis and in maintenance phase treatment with Epoetin...||2007-05-10||due-trials|
|Not reported||2005-000144-87||Long-term efficacy and safety of subcutaneous administration of XM01 in chronic renal failure patients and comparison of once-weekly with three-times weekly administration of XM01 - A multinational, m...||2008-01-21||due-trials|
|Not reported||2007-005349-39||Dose-finding of a fixed dose XM22 in patients with breast cancer receiving 4 cycles of chemotherapy versus 6 mg Neulasta®||2009-12-10||due-trials|
|Completed, but no date, and reported results||2009-015999-10||Efficacy and Safety of XM22 compared to pegfilgrastim in patients with breast cancer receiving chemotherapy. A multinational, multicentre, randomised, double-blind controlled study||bad-data|
|Reported results||2009-016000-22||Efficacy and safety of XM22 in patients with non small cell lung cancer receiving cisplatin / etoposide chemotherapy. A multinational, multicentre, randomised, double-blind placebo-controlled study||2011-12-19||due-trials|
|Not reported||2009-017674-20||Efficacy, safety and tolerability of XM17 compared to Gonal-f® in women undergoing assisted reproductive technologies. A multi-national, multi-centre, randomised, controlled, assessor-blind, parallel ...||2011-09-18||due-trials|